By Matt Grossman

 

Sanofi's Sarclisa, an immunotherapy for patients with multiple myeloma, has been approved by Canada's health authority, Sanofi said Wednesday.

The treatment was approved to treat patients who have had at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa was approved to be used in conjunction with pomalidomide and dexamethasone.

The drug's approval was based on a study that showed statistically significant improvement in patients' progression-free survival, Sanofi said.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

July 08, 2020 07:50 ET (11:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Sanofi
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Sanofi